Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

95.55 -1.08 (-1.12%)
Official Closing Price Updated: 7:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
This list of top-selling drugs could look drastically different in a few years. 
Via The Motley Fool
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
The unveiled prices follow months of back-and-forth negotiation between the government and the companies. 
Via Investor's Business Daily
2 Dow Jones Stocks to Buy Hand Over Fist Right Now
Despite a possible recession, these two Dow Jones stocks are still a buy. 
Via The Motley Fool
Topics Economy Stocks
Exposures Economy US Equities
In-Depth Analysis: Merck &amp; Co Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Uncovering Dividend Opportunities with NYSE:MRK.
Balancing Dividends and Fundamentals: The Case of MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth. 
Via InvestorPlace
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims to advance Merck's pipeline for treating B-cell malignancies and... 
Via Benzinga
'I'm Not Proud Of Myself': Jim Cramer Says He Bought 'Worst Of The Three' GE Stocks
Jim Cramer recommends buying Merck (MRK) due to faith in CEO Robert Davis. He advises against Teladoc (TDOC) due to Cathie Wood's selling. He remains committed to Palo Alto Networks (PANW). He suggests... 
Via Benzinga
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
Merck discontinues the Phase 3 KeyVibe-008 trial for the fixed-dose combination of vibostolimab and Keytruda in extensive-stage small cell lung cancer due to futility in overall survival and increased... 
Via Benzinga
The 3 Best Biotech Stocks to Buy in August 2024
These biotech stocks are leading the way with groundbreaking therapies and robust fundamentals offering superb upside ahead. 
Via InvestorPlace
NYSE:MRK is an undervalued gem with solid fundamentals.
In a market where value is scarce, MERCK & CO. INC. (NYSE:MRK) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
Palantir’s AI Evolution: Strategic Shift Or Marketing Ploy?
Palantir is outgrowing government contract reliance and the AI shift is producing a robust revenue model so far. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Dividend Stocks to Buy and Never Sell
These two are rock-solid businesses with strong dividend programs. 
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Shares of the rare disease drugmaker are already up more than 40% over the past year. 
Via The Motley Fool
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy... 
Via Benzinga
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage... 
Via Benzinga
Merck's Blockbuster Vaccine Gardasil Sales In China: Analyst Highlights Challenges and Opportunities
Goldman Sachs discusses Gardasil's performance in China with Merck's Joe Romanelli. Gardasil faces challenges due to market issues and partner Zhifei's operational problems, impacting Q2 sales. Despite... 
Via Benzinga
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Moderna sustained a rare downgrade on Monday following its guidance cut for the year. 
Via Investor's Business Daily
Is It Time to Buy July's Worst-Performing Dow Jones Stocks?
Most Dow stocks were winners last month, but not these. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
MicroStrategy, Intel And Moderna Are Among Top 12 Large Cap Losers Last Week (July 28-August 3): Are The Others In Your Portfolio?
12 worst-performing large-cap stocks in the last week. Symbotic, Intel, Snap, Moderna, Mobileye, Pinterest, Arm, Entegris, Atlassian, MicroStrategy, New Oriental, and Western Digital. 
Via Benzinga
2 Ultra-High-Yield Dividend Stocks to Buy in August and Hold at Least a Decade
With an average yield above 7% at recent prices, these stocks could give your passive income stream a big boost. 
Via The Motley Fool
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from... 
Via Benzinga
Exposures COVID-19
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
Figuring out the hottest biotech stocks can be as simple as looking at the most traded stocks by volume in the last 24 hours. 
Via InvestorPlace
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
Moderna's vaccine magic is slowly losing its charm, as evidenced by the warning the company issued on Thursday but Ark reposed its faith in the company. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.